The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Galan Lithium
GLN:AU
Trident Royalties PLC
TDTRF
Impact Minerals Limited
IPT:AU
Carbon Done Right
KLX:CC
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
Diffusion Pharmaceuticals Announces Allowances of Two U.S. Patent Applications
Feb. 01, 2018 09:55AM PST
Biotech InvestingDiffusion Pharmaceuticals (NASDAQ:DFFN) a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, announced receipt of two patent application allowances relating to its lead compound trans sodium crocetinate in the U.S. The allowances include claims for both method of use and composition of matter. As quoted in the press release: “We have worked …
Diffusion Pharmaceuticals (NASDAQ:DFFN) a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, announced receipt of two patent application allowances relating to its lead compound trans sodium crocetinate in the U.S. The allowances include claims for both method of use and composition of matter.
As quoted in the press release:
“We have worked hard to ensure our discoveries are protected and are grateful to receive these patent application allowances. We look forward to these patents being issued in the coming months,” said David Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals.
Outlook Reports
Featured Biotech Investing Stocks
Browse Companies
MARKETS
COMMODITIES
| Commodities | |||
|---|---|---|---|
| Gold | 2312.32 | -21.07 | |
| Silver | 26.95 | -0.36 | |
| Copper | 4.48 | -0.03 | |
| Oil | 81.94 | +0.04 | |
| Heating Oil | 2.57 | 0.00 | |
| Natural Gas | 1.79 | 0.00 | |
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.